{"id":"toripalimab-monotherapy","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Rash"},{"rate":"5-10%","effect":"Pyrexia"}]},"_chembl":{"chemblId":"CHEMBL4297843","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking the PD-1/PD-L1 interaction, toripalimab allows T cells to recognize and attack cancer cells more effectively. This mechanism is thought to be responsible for its anti-tumor activity in various types of cancer.","oneSentence":"Toripalimab is a PD-1 inhibitor that blocks the PD-1 receptor on T cells, preventing its interaction with PD-L1 on tumor cells and thereby enhancing anti-tumor immune responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:39:27.908Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer, PD-L1 positive"},{"name":"Nasopharyngeal carcinoma"}]},"trialDetails":[{"nctId":"NCT07480733","phase":"PHASE2","title":"Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2026-04-02","conditions":"Advanced Malignant Solid Tumors","enrollment":480},{"nctId":"NCT05635643","phase":"PHASE1","title":"Study of CHS-114 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Coherus Oncology, Inc.","startDate":"2022-12-15","conditions":"Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma","enrollment":87},{"nctId":"NCT07423078","phase":"PHASE2","title":"Window of Opportunity in Preserving Laryngeal Function Trial","status":"NOT_YET_RECRUITING","sponsor":"Matthew Spector","startDate":"2026-03-31","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Locally Advanced Laryngeal Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma","enrollment":87},{"nctId":"NCT07281976","phase":"PHASE1, PHASE2","title":"A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Nanjing Leads Biolabs Co.,Ltd","startDate":"2026-01-27","conditions":"Triple Negative Breast Cancer","enrollment":220},{"nctId":"NCT05518045","phase":"PHASE1, PHASE2","title":"A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"LaNova Medicines Limited","startDate":"2022-08-26","conditions":"Advanced Solid Tumor","enrollment":392},{"nctId":"NCT06984588","phase":"PHASE2, PHASE3","title":"A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"TJ Biopharma Co., Ltd.","startDate":"2024-03-28","conditions":"Non Small Cell Lung Cancer","enrollment":450},{"nctId":"NCT07371897","phase":"PHASE3","title":"Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-06-30","conditions":"Head and Neck Squamous Cell Carcinoma HNSCC","enrollment":154},{"nctId":"NCT07332221","phase":"PHASE3","title":"Application of Toripalimab as Adjuvant Therapy After Esophageal Cancer Surgery: A Multicenter Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2026-01-20","conditions":"Esophageal Cancer","enrollment":435},{"nctId":"NCT04501276","phase":"PHASE1","title":"A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients","status":"COMPLETED","sponsor":"Adagene Inc","startDate":"2020-09-23","conditions":"Advanced/Metastatic Solid Tumors","enrollment":72},{"nctId":"NCT06283134","phase":"PHASE1","title":"A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"China Medical University, China","startDate":"2026-03","conditions":"Colorectal Cancer Metastatic","enrollment":60},{"nctId":"NCT06380309","phase":"EARLY_PHASE1","title":"A Clinical Study on Evaluating Intravenous Administration of IDOV-SAFE","status":"RECRUITING","sponsor":"Peking University","startDate":"2024-05-06","conditions":"Advanced Malignant Solid Tumor of Digestive System","enrollment":89},{"nctId":"NCT07282262","phase":"PHASE2","title":"An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-05-01","conditions":"Biliary Tract Cancer","enrollment":300},{"nctId":"NCT07272291","phase":"PHASE2","title":"A Phase II Study of Toripalimab Plus Chemotherapy and Low-Dose Radiotherapy for Neoadjuvant Therapy-Refractory Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-12-25","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":48},{"nctId":"NCT07099430","phase":"PHASE1, PHASE2","title":"A Trial of LBL-024 Monotherapy, LBL-024 Combined With LBL-007 or Toripalimab in Patients With Advanced Melanoma","status":"RECRUITING","sponsor":"Nanjing Leads Biolabs Co.,Ltd","startDate":"2025-09-05","conditions":"Advanced Melanoma","enrollment":200},{"nctId":"NCT04394975","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer","status":"COMPLETED","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2020-08-20","conditions":"Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1","enrollment":421},{"nctId":"NCT03926338","phase":"PHASE2","title":"Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2019-05-10","conditions":"Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H)","enrollment":270},{"nctId":"NCT04374877","phase":"PHASE1","title":"Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Coherus Oncology, Inc.","startDate":"2020-04-22","conditions":"Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma","enrollment":145},{"nctId":"NCT07189793","phase":"PHASE2","title":"Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-10","conditions":"Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Carcinoma in Situ of Bladder","enrollment":106},{"nctId":"NCT07070479","phase":"PHASE2","title":"Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial","status":"RECRUITING","sponsor":"Ming-Yuan Chen","startDate":"2025-06-24","conditions":"Recurrent or Metastatic Nasopharyngeal Carcinoma","enrollment":208},{"nctId":"NCT06145308","phase":"PHASE2","title":"Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing","status":"RECRUITING","sponsor":"Peking Union Medical College","startDate":"2023-08-15","conditions":"Salivary Gland Carcinoma, Precision Therapy","enrollment":39},{"nctId":"NCT06088004","phase":"PHASE1, PHASE2","title":"Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Suzhou Abogen Biosciences Co., Ltd.","startDate":"2023-09-28","conditions":"Solid Tumor, Adult","enrollment":218},{"nctId":"NCT07047001","phase":"PHASE2","title":"Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dong Wen","startDate":"2025-04-24","conditions":"Renal Cell Carcinoma (RCC), Adjuvant","enrollment":60},{"nctId":"NCT04322006","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of TJ004309 for Advanced Solid Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"TJ Biopharma Co., Ltd.","startDate":"2020-05-09","conditions":"Advanced Solid Tumor","enrollment":376},{"nctId":"NCT06577532","phase":"EARLY_PHASE1","title":"Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid Tumors","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-09-24","conditions":"Pancreatic Neoplasms, Other Solid Tumors","enrollment":56},{"nctId":"NCT06980155","phase":"EARLY_PHASE1","title":"XP-005 Personalized Vaccine Alone or in Combination With Toripalimab for the Prevention of Relapse After Remission in Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2025-05-30","conditions":"Acute Myeloid Leukemia","enrollment":60},{"nctId":"NCT05757492","phase":"PHASE1","title":"Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Coherus Oncology, Inc.","startDate":"2023-04-26","conditions":"Advanced Solid Tumor, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma","enrollment":22},{"nctId":"NCT06823427","phase":"PHASE2","title":"9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma","status":"RECRUITING","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","startDate":"2025-01-17","conditions":"Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent","enrollment":60},{"nctId":"NCT06571422","phase":"PHASE1","title":"Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2024-10-23","conditions":"Advanced Malignant Solid Tumors","enrollment":93},{"nctId":"NCT05188664","phase":"PHASE1, PHASE2","title":"Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"LaNova Australia Pty Limited","startDate":"2022-05-10","conditions":"Advanced Solid Tumor","enrollment":20},{"nctId":"NCT06388031","phase":"PHASE2","title":"ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-08-09","conditions":"Non-small Cell Lung Cancer","enrollment":27},{"nctId":"NCT05963490","phase":"PHASE2","title":"Regorafenib Alone or in Combination With Hypofractionated/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-04-25","conditions":"Microsatellite Stable Metastatic Colorectal Cancer","enrollment":108},{"nctId":"NCT06105008","phase":"PHASE2","title":"Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer","status":"WITHDRAWN","sponsor":"RemeGen Co., Ltd.","startDate":"2024-12-20","conditions":"Breast Neoplasms","enrollment":""},{"nctId":"NCT04645069","phase":"PHASE1, PHASE2","title":"ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors","status":"COMPLETED","sponsor":"Adagene Inc","startDate":"2021-03-15","conditions":"Advanced/Metastatic Solid Tumors","enrollment":58},{"nctId":"NCT06385730","phase":"PHASE2","title":"Neoadjuvant PD-1 Blockade for Elderly Esophageal Squamous Cell Carcinoma (BLESS)","status":"RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2024-06-17","conditions":"Esophageal Cancer","enrollment":60},{"nctId":"NCT05579275","phase":"EARLY_PHASE1","title":"Evaluate the Safety and Tolerability of JCXH-212 Monotherapy and Combined With Toripalimab in the Treatment of Malignant Solid Tumors","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2023-02-06","conditions":"Malignant Solid Tumors","enrollment":24},{"nctId":"NCT03874897","phase":"PHASE1","title":"Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.","status":"COMPLETED","sponsor":"Peking University","startDate":"2019-03-26","conditions":"Advanced Solid Tumor","enrollment":134},{"nctId":"NCT06283121","phase":"PHASE2","title":"A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"China Medical University, China","startDate":"2024-04-02","conditions":"Gastric Cancer, Metastatic","enrollment":30},{"nctId":"NCT06261138","phase":"","title":"Survival Analysis: TACE vs. Combination Therapy in HCC","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2019-02-01","conditions":"Hepatocellular Carcinoma","enrollment":279},{"nctId":"NCT04137900","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies","status":"RECRUITING","sponsor":"TopAlliance Biosciences","startDate":"2019-10-30","conditions":"Advanced Unresectable Solid Tumor, Metastatic Solid Tumor","enrollment":499},{"nctId":"NCT05729646","phase":"PHASE2","title":"Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Yu jiren","startDate":"2023-05-31","conditions":"Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Mismatch Repair Deficiency","enrollment":90},{"nctId":"NCT03810339","phase":"PHASE2","title":"Toripalimab as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-01-15","conditions":"Solid Tumor, Advanced Cancer","enrollment":35},{"nctId":"NCT05699811","phase":"PHASE1, PHASE2","title":"IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2023-02-23","conditions":"Locally Advanced or Metastatic Solid Tumors","enrollment":40},{"nctId":"NCT05650203","phase":"PHASE1","title":"A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies","status":"WITHDRAWN","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2023-03-31","conditions":"Primary Condition: Advanced Tumors","enrollment":""},{"nctId":"NCT05332496","phase":"","title":"TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC","status":"UNKNOWN","sponsor":"Zhongda Hospital","startDate":"2022-12-28","conditions":"Hepatocellular Carcinoma","enrollment":220},{"nctId":"NCT03864211","phase":"PHASE1, PHASE2","title":"Thermal Ablation Followed by Immunotherapy for HCC","status":"UNKNOWN","sponsor":"Xiangya Hospital of Central South University","startDate":"2019-06-15","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":145},{"nctId":"NCT05253105","phase":"PHASE1","title":"A Clinical Study of TAB006 in Patients With Previously Treated, Advanced Malignancies","status":"WITHDRAWN","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2022-03-15","conditions":"Previously Treated, Advanced, Malignancies","enrollment":""},{"nctId":"NCT05274438","phase":"PHASE2","title":"Imatinib and Toripalimab in Patients With Locally Advanced/Metastatic Melanoma Harbored With CKIT Mut","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2021-01-26","conditions":"Advanced Melanoma","enrollment":37},{"nctId":"NCT05173142","phase":"PHASE1, PHASE2","title":"HMPL-453 (FGFR Inhibitor) in Combination With Chemotherapy or Anti-PD-1 Antibody in Advanced Solid Tumors","status":"UNKNOWN","sponsor":"Hutchison Medipharma Limited","startDate":"2022-01-22","conditions":"Solid Tumor","enrollment":141},{"nctId":"NCT04483219","phase":"PHASE2","title":"Tyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma.","status":"UNKNOWN","sponsor":"China Medical University, China","startDate":"2020-07-24","conditions":"MSS, pMMR, Metastatic Colorectal Adenocarcinoma","enrollment":53},{"nctId":"NCT05061628","phase":"PHASE1","title":"The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumor","status":"UNKNOWN","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2021-04-21","conditions":"Advanced Tumors","enrollment":176},{"nctId":"NCT03811379","phase":"PHASE2","title":"Toripalimab as Monotherapy for Patients With Small Cell Carcinoma of Esophagus Who Failed Chemotherapy","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2018-11-21","conditions":"Small Cell Carcinoma of Esophagus, Advanced Cancer","enrollment":43}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Toripalimab monotherapy","genericName":"Toripalimab monotherapy","companyName":"Henan Cancer Hospital","companyId":"henan-cancer-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Toripalimab is a programmed cell death protein 1 antagonist, classified as an antibody, used as a monotherapy for treating advanced urothelial carcinoma. It is indicated for conditions such as urothelial carcinoma, urothelial carcinoma of the bladder, and urothelial carcinoma of the renal pelvis and ureter.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}